Therapeutics Platform
Next-Generation Psychedelic Medicines
Prodelic Technologies is a preclinical-stage biotechnology company dedicated to the development of non-hallucinogenic neuroplastogens—a breakthrough class of therapeutics designed to rapidly rewire the brain and restore mental health without the psychedelic "trip."
What Are Non-Hallucinogenic Neuroplastogens?
Non-hallucinogenic neuroplastogens are a novel class of compounds engineered to trigger the rapid growth of synaptic connections (neuroplasticity) without the characteristic perceptual distortions and cognitive disruptions of traditional psychedelics. By decoupling therapeutic plasticity from hallucinogenic potential, Prodelics is creating a scalable medical model that enables safe, accessible, and high-efficacy mental healthcare across broad patient populations.
Molecular Mechanism: Rewiring Without the "Trip"
Non-hallucinogenic neuroplastogens are a novel class of compounds engineered to trigger the rapid growth of synaptic connections (neuroplasticity) without the characteristic perceptual distortions and cognitive disruptions of traditional psychedelics. By selectively activating intracellular signaling pathways such as TrkB (the receptor for brain-derived neurotrophic factor, BDNF) and mTOR, these molecules promote structural remodeling in the prefrontal cortex—the brain region responsible for mood regulation and executive function. Unlike hallucinogenic counterparts that broadly stimulate the 5-HT2A receptor to induce subjective experiences, these targeted medicinal chemists have decoupled therapeutic plasticity from hallucinogenic potential, allowing for safe, broad-spectrum application across chronic psychiatric conditions including MDD, TRD, and PTSD without the need for intensive clinical oversight.
Clinical Indications & Target Diseases
Major Neuropsychiatric Disorders
Non-hallucinogenic neuroplastogens represent a transformational therapy for the most prevalent mental health conditions, including Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and Generalized Anxiety Disorder (GAD). By directly addressing the loss of synaptic density associated with these conditions, our compounds offer rapid and sustained relief where traditional SSRIs often fail.
PTSD & Trauma-Related Stress
Post-Traumatic Stress Disorder involves deeply ingrained neural pathways associated with fear and hypervigilance. Our platform facilitates the rewiring of these circuits, promoting 'fear extinction' and cognitive flexibility. Because these treatments are non-hallucinogenic, they can be utilized in varied therapeutic settings, providing a scalable solution for veterans and civilian trauma survivors.
Neurodegenerative & Substance Use Disorders
Beyond psychiatry, neuroplastogens show early promise in slowing cognitive decline in Alzheimer’s and Parkinson’s disease by maintaining neuronal health. Additionally, by aiding in the regulation of reward pathways, they offer a new tool for managing Substance Use Disorder (SUD), helping patients break the cycle of addiction through neural reorganization.
Delivery Model: Scalable, Accessible, Take-Home Care
Removing the hallucinogenic 'trip' eliminates the need for intensive 6-8 hour monitoring sessions. This breakthrough allows clinics to treat more patients effectively, drastically reducing cost barriers and moving neuroplastogens toward home-based administration for long-term mental health maintenance.
By integrating non-hallucinogenic compounds with our specialized delivery systems—transmucosal, intranasal, and microneedle platforms—we ensure precise bioavailability and temporal control. Prodelics is building the infrastructure necessary to make non-hallucinogenic neuroplastogens the new gold standard.
Stakeholder Value Propositions
For Patients
Access to rapid-acting treatments that fit a take-home model, providing relief without the side effects, stigma, or logistical challenges of hallucinogenic trips.
For Providers
High-throughput care delivery. Clinics can manage more patients without reserved 8-hour rooms or high staffing ratios for monitoring safety.
For Payers (Insurance)
Lower total cost of care. Non-hallucinogenic options remove the billable hours of clinical supervision required by the FDA’s REMS for psychedelic medicines.
For Pharma & Investors
Mass-market potential. Clinical indication focus allows for pharmaceutical scale, standardization of dosing, and broad intellectual property protection on novel chemical entities.
The Prodelics Advantage:
Partner With Us
The potential for non-hallucinogenic neuroplastogens extends far beyond immediate psychiatric indicators. As we refine our platform, we explore applications in neurorehabilitation (stroke recovery), cognitive enhancement, and the treatment of neurodegenerative diseases. By mapping the neuroplastic genome, Prodelics is creating a sustainable future where mental health is managed with the same precision and accessibility as any other chronic medical condition.